These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1846464)

  • 1. Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials.
    Snydman DR; Werner BG; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS; Strom TB; Carpenter CB
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1357-60. PubMed ID: 1846464
    [No Abstract]   [Full Text] [Related]  

  • 2. A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial.
    Snydman DR; Werner BG; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS; Strom TB; Carpenter CB
    Transplant Proc; 1988 Dec; 20(6 Suppl 8):24-30. PubMed ID: 2849222
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: analysis of usage under treatment IND status. The Treatment IND Study Group.
    Werner BG; Snydman DR; Freeman R; Rohrer R; Tilney NL; Kirkman RL
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1441-3. PubMed ID: 8382875
    [No Abstract]   [Full Text] [Related]  

  • 4. Review of the efficacy of cytomegalovirus immune globulin in the prophylaxis of CMV disease in renal transplant recipients.
    Snydman DR
    Transplant Proc; 1993 Oct; 25(5 Suppl 4):25-6. PubMed ID: 8212304
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
    Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does intravenous immunoglobulin prevent primary cytomegalovirus disease in kidney transplant recipients?
    Khawand N; Light JA; Brems W; Aquino A; Ali A
    Transplant Proc; 1989 Feb; 21(1 Pt 2):2072-4. PubMed ID: 2540555
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of cytomegalovirus infection in bone marrow transplant recipients by prophylaxis with an intravenous, hyperimmune cytomegalovirus globulin.
    Condie RM; O'Reilly RJ
    Birth Defects Orig Artic Ser; 1984; 20(1):327-44. PubMed ID: 6329370
    [No Abstract]   [Full Text] [Related]  

  • 8. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
    Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A
    Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune globulin (GAMMAGARD) prophylaxis of CMV infections in patients undergoing organ transplantation and allogeneic bone marrow transplantation.
    Fehir KM; Decker WA; Samo T; Young JB; Lederer E; Lawrence EC
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3107-9. PubMed ID: 2539691
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients--a meta-analysis.
    Glowacki LS; Smaill FM
    Clin Transplant; 1994 Feb; 8(1):10-8. PubMed ID: 8136560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of prospective matching for cytomegalovirus status in renal transplant recipients.
    Ludwin D; White N; Tsai S; Chernesky M; Achong M; Smith EK
    Transplant Proc; 1987 Aug; 19(4):3433-4. PubMed ID: 3039700
    [No Abstract]   [Full Text] [Related]  

  • 12. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
    Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
    Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus disease prophylaxis in seronegative recipients of kidneys from seropositive donors by combination of cytomegalovirus-hyperimmune globulin and low-dose acyclovir.
    MacDonald AS; Belitsky P; Cohen A; Lee S
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1355-6. PubMed ID: 1846463
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytomegalovirus immune globulin in renal-transplant recipients.
    N Engl J Med; 1988 Apr; 318(16):1065-7. PubMed ID: 2832759
    [No Abstract]   [Full Text] [Related]  

  • 15. Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease.
    Conti DJ; Freed BM; Lempert N
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1421-2. PubMed ID: 8382867
    [No Abstract]   [Full Text] [Related]  

  • 16. Should heart-lung transplant donors and recipients be matched according to cytomegalovirus serologic status?
    Novick RJ; Menkis AH; McKenzie FN; Reid KR; Ahmad D
    J Heart Transplant; 1990; 9(6):699-706. PubMed ID: 2177496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of infection and acute rejection after cytomegalovirus immune globulin prophylaxis in renal transplantation.
    Basadonna G; Feria A; Perez R; Klein H; Sturges M; Colquhoun S
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):52-3. PubMed ID: 7940976
    [No Abstract]   [Full Text] [Related]  

  • 18. Incidence of cytomegalovirus infection and effects of cytomegalovirus immune globulin prophylaxis after orthotopic liver transplantation.
    Saliba F; Gugenheim J; Samuel D; Bismuth A; Mathieu D; Serres C; Bismuth H
    Transplant Proc; 1987 Oct; 19(5):4081-2. PubMed ID: 2823435
    [No Abstract]   [Full Text] [Related]  

  • 19. [Specific anti-cytomegalovirus immunoglobulins in the prevention of cytomegalovirus infections in bone marrow allografts].
    Huart JJ; Baume D; Jouet JP
    Ann Med Interne (Paris); 1987; 138(5):372-4. PubMed ID: 2823667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of cytomegalovirus infection in kidney recipients.
    Bilgin N; Karakayali H; Moray G; Akkoç H; Turan M
    Transplant Proc; 1996 Aug; 28(4):2314-5. PubMed ID: 8769233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.